Vialwirebiotech, curated
November 21, 2026, 5:08 AM
November 20, 2026
- 6:43 PM · STAT News
- 2:53 PM · BioPharma Dive2:53 PMWill the first approved psychedelic become a blockbuster? — BioPharma Dive
- 1:00 PM · FT — Pharmaceuticals1:00 PMDirectors’ Deals: Hikma executive sells £1.1mn of shares — FT — Pharmaceuticals
- 11:00 AM · BioWorld11:00 AM$1B-plus deal takes Innogen's approved GLP-1 abroad — BioWorld
- 11:00 AM · BioWorld11:00 AMFDA seeks advice on pathogen-agnostic sequencing — BioWorld
- 11:00 AM · BioWorld11:00 AMUK: Gene therapy to now cover synthetic DNA and CRISPR editing — BioWorld
- 11:00 AM · BioWorld11:00 AMTwo new drugs for hepatitis B, herpes gain US approval in October — BioWorld
- 9:59 AM · Pharmaceutical Technology9:59 AMMSD and Isomorphic join forces to develop oncology drugs — Pharmaceutical Technology
- 9:48 AM · Pharmaceutical Executive9:48 AM<![CDATA[Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks]]> — Pharmaceutical Executive
- 9:01 AM · STAT News
- 8:29 AM · Drug Discovery World8:29 AMMilestone reached for novel cystic fibrosis therapy — Drug Discovery World
- 7:17 AM · FT — Pharmaceuticals7:17 AMNew pancreatic cancer drug halts tumour growth in 90% of patients — FT — Pharmaceuticals
- 6:37 AM · Pharmaceutical Technology6:37 AMNovartis CEO leans on surge of pipeline readouts to quell growth fears — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMPartners advance small molecule degraders for neurodegeneration — Drug Discovery World
November 19, 2026
- 7:00 PM · STAT News
- 1:14 PM · Bloomberg — Technology1:14 PMAnthropic Makes History on Wall Street — Bloomberg — Technology
- 12:00 PM · BioWorld12:00 PMRegulatory: Approvals for Klygefa, Wilserdly, Lembaz and Nelkarmi — BioWorld
- 11:55 AM · Pharmaceutical Technology11:55 AMRecursion CEO details novel Phase III endpoint for rare disease drug — Pharmaceutical Technology
- 11:42 AM · BioPharma Dive11:42 AMChina could ‘corner’ biopharmaceutical sector with new plan, US panel warns — BioPharma Dive
- 11:00 AM · BioWorld11:00 AMNobel science goes commercial with Japan's world-first iPSC nods — BioWorld
- 11:00 AM · BioWorld11:00 AMSanofi wins FDA nod for Infilbray in GD3; gene therapy next? — BioWorld
- 11:00 AM · BioWorld11:00 AMRegeneron’s siRNA Livsayis wins FDA nod for gMG — BioWorld
- 11:00 AM · BioWorld11:00 AMFDA threatens to pull liquid statin from US market — BioWorld
- 11:00 AM · BioWorld11:00 AMChina’s dual reimbursement tracks widen access to innovative drugs — BioWorld
- 10:49 AM · Pharmaceutical Technology10:49 AMEllipses Pharma plots London listing that could end British biotech IPO drought — Pharmaceutical Technology
- 9:33 AM · Pharmaceutical Technology9:33 AMAbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics — Pharmaceutical Technology
- 8:00 AM · BioWorld8:00 AMPreclinical proof-of-concept for Mammoth’s chylomicronemia therapy — BioWorld
- 8:00 AM · BioWorld8:00 AMEvotec and BMS gain CELMoD IND acceptance — BioWorld
- 8:00 AM · BioWorld8:00 AMHutchmed reports preclinical data on HMPL-A830 — BioWorld
- 8:00 AM · BioWorld8:00 AMAkagera Medicines awarded additional funding for mRNA TB vaccine — BioWorld
- 8:00 AM · BioWorld8:00 AMSeries C financing to advance Vitrivax Lyme vaccine into clinic — BioWorld
- 8:00 AM · BioWorld8:00 AMGrant supports Asgard Therapeutics’ AT-108 toward clinic — BioWorld
- 8:00 AM · BioWorld8:00 AMChina NMPA accepts IND for Harbour Biomed’s LET-003 for obesity — BioWorld
- 8:00 AM · BioWorld8:00 AMPfizer’s CEACAM5 ADC shows broad preclinical antitumor activity — BioWorld
- 8:00 AM · BioWorld8:00 AMPTC Therapeutics reports PTC-844 preclinical and clinical data — BioWorld
- 6:41 AM · Pharmaceutical Technology6:41 AMPfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies — Pharmaceutical Technology
- 6:30 AM · STAT News
- 6:00 AM · Drug Discovery World6:00 AMSofinnova closes €725 life sciences fund — Drug Discovery World